Cargando…

APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer

BACKGROUND: Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3B (APOBEC3B) is a gene editing enzyme with cytidine deaminase activity and high expression of its mRNA in breast tumors have been shown to be associated with progressive cases and poor prognosis. In this study, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiki, Yoshitaka, Yamamoto, Yutaka, Sueta, Aiko, Yamamoto-Ibusuki, Mutsuko, Goto-Yamaguchi, Lisa, Tomiguchi, Mai, Takeshita, Takashi, Iwase, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078135/ https://www.ncbi.nlm.nih.gov/pubmed/30093965 http://dx.doi.org/10.18632/oncotarget.25495

Ejemplares similares

Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence
por: Sueta, Aiko, et al.
Publicado: (2017)

Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary breast cancer
por: Tomiguchi, Mai, et al.
Publicado: (2016)

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2018)

Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients
por: Takeshita, Takashi, et al.
Publicado: (2017)

Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer
por: Hayashi, Mitsuhiro, et al.
Publicado: (2015)

A progressive and refractory case of breast cancer with Cowden syndrome
por: Sueta, Aiko, et al.
Publicado: (2022)

The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer
por: Fujiwara, Saori, et al.
Publicado: (2014)

An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
por: Sueta, Aiko, et al.
Publicado: (2014)

Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
por: Takeshita, Takashi, et al.
Publicado: (2015)

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
por: Takeshita, Takashi, et al.
Publicado: (2016)

Clinical features of lenvatinib treatment in elderly patients with advanced thyroid cancer
por: Suyama, Koichi, et al.
Publicado: (2017)

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy
por: Omoto, Yoko, et al.
Publicado: (2015)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
por: Kosaka, Yoshimasa, et al.
Publicado: (2020)

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer
por: Yamamoto, Satoko, et al.
Publicado: (2013)

The role of exosomal microRNAs; focus on clinical applications in breast cancer
por: Sueta, Aiko, et al.
Publicado: (2019)

A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character
por: Hayashi, Mitsuhiro, et al.
Publicado: (2013)

PTIP Associated protein 1, PA1, Is an Independent Prognostic Factor for Lymphnode Negative Breast Cancer
por: Takeshita, Takashi, et al.
Publicado: (2013)

The Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer
por: Shiota, Takuya, et al.
Publicado: (2016)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival
por: Rezano, Andri, et al.
Publicado: (2013)

High density of CD204‐positive macrophages predicts worse clinical prognosis in patients with breast cancer
por: Miyasato, Yuko, et al.
Publicado: (2017)

Cardiac computed tomography‐derived myocardial tissue characterization after anthracycline treatment
por: Egashira, Koichi, et al.
Publicado: (2022)

Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion
por: Okumura, Yasuhiro, et al.
Publicado: (2008)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Cardiac computed tomography-derived extracellular volume fraction in late anthracycline-induced cardiotoxicity
por: Egashira, Koichi, et al.
Publicado: (2021)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review
por: Chainitikun, Sudpreeda, et al.
Publicado: (2021)

Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
por: Inari, Hitoshi, et al.
Publicado: (2020)

Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020)

Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype
por: Fukuda, Takayo, et al.
Publicado: (2016)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients
por: Sasanpour, Pegah, et al.
Publicado: (2018)

Influences on pathologic complete response in breast cancer patients after neoadjuvant chemotherapy
por: Müller, Carolin, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
por: Usui, Yuki, et al.
Publicado: (2021)

GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development
por: Kuwahara, Kazuhiko, et al.
Publicado: (2016)

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
por: Asakawa, Hideki, et al.
Publicado: (2010)

Pathological Complete Response following Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma with Mammary Paget's Disease: A Case Report
por: Goto, Wataru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hgnt87u4roqc0r7q207g40l38h